Long-acting inhalation treatment and the risk of urinary tract infection textendash a symmetry analysis

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

Resumé

Background: Long-acting muscarinic antagonists (LAMA) have previously been associated with increased risk of urinary tract infections (UTI), but the association is not well-established. Further, it has not been proven whether long-acting inhalation treatment (LAIT [long-acting bronchodilators] and inhaled corticosteroids [ICS]) show the same association. The study aimed to assess the association between LAIT and UTI treatment.Methods A prescription sequence symmetry analysis was employed on all Danish residents aged >=18 years from 2000-2016, who filled their first ever prescription for LAIT and a prescription of antibiotics targeting UTI within an interval of 30 days before or after the LAIT initiation. We calculated the sequence ratio (SR) and corresponding 95% confidence intervals. The SR is the ratio between subjects with LAIT prescribed before UTI treatment and subjects with LAIT prescribed after, which is a valid estimate of the incidence rate ratio. The attributable number of post-LAIT UTI treatment was also calculated.Results: A total of 36,048 persons were identified initiating their first LAIT and UTI treatment within a 30-day days. Of those, 26,017 (72 were females; 1,948 initiated LAIT before and 1,663 initiated LAIT after UTI treatment (SR 1.17, 1.10-1.25). The attributable number was 285 (14.6. Male- and female SR was 1.30 (95%CI 1.16-1.48) and 1.12 (1.04-1.21), respectively. Patients with a CCI>=3 had the strongest association (SR 1.35, 1.15-1.61). The SR initiating LAMA, LABA, and ICS was 1.02 (0.83-1.28), 1.24 (0.99-1.58), and 1.19 (1.07-1.31) respectively.Conclusions: We found a weak association between the initiation of UTI treatment for ICS but not for LABA or LAMA.FootnotesCite this article as: European Respiratory Journal 2018 52: Suppl. 62, PA2270.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
OriginalsprogUdefineret/Ukendt
ArtikelnummerPA2270
TidsskriftEuropean Respiratory Journal
Vol/bind52
Udgave nummerSuppl. 62
Antal sider1
ISSN0903-1936
DOI
StatusUdgivet - 2018
BegivenhedERS International Congress 2018 - Paris, Frankrig
Varighed: 15. sep. 201819. sep. 2018

Konference

KonferenceERS International Congress 2018
LandFrankrig
ByParis
Periode15/09/201819/09/2018

Citer dette

@article{b362f362573743ceb963ca827e4e2ccc,
title = "Long-acting inhalation treatment and the risk of urinary tract infection textendash a symmetry analysis",
abstract = "Background: Long-acting muscarinic antagonists (LAMA) have previously been associated with increased risk of urinary tract infections (UTI), but the association is not well-established. Further, it has not been proven whether long-acting inhalation treatment (LAIT [long-acting bronchodilators] and inhaled corticosteroids [ICS]) show the same association. The study aimed to assess the association between LAIT and UTI treatment.Methods A prescription sequence symmetry analysis was employed on all Danish residents aged >=18 years from 2000-2016, who filled their first ever prescription for LAIT and a prescription of antibiotics targeting UTI within an interval of 30 days before or after the LAIT initiation. We calculated the sequence ratio (SR) and corresponding 95{\%} confidence intervals. The SR is the ratio between subjects with LAIT prescribed before UTI treatment and subjects with LAIT prescribed after, which is a valid estimate of the incidence rate ratio. The attributable number of post-LAIT UTI treatment was also calculated.Results: A total of 36,048 persons were identified initiating their first LAIT and UTI treatment within a 30-day days. Of those, 26,017 (72 were females; 1,948 initiated LAIT before and 1,663 initiated LAIT after UTI treatment (SR 1.17, 1.10-1.25). The attributable number was 285 (14.6. Male- and female SR was 1.30 (95{\%}CI 1.16-1.48) and 1.12 (1.04-1.21), respectively. Patients with a CCI>=3 had the strongest association (SR 1.35, 1.15-1.61). The SR initiating LAMA, LABA, and ICS was 1.02 (0.83-1.28), 1.24 (0.99-1.58), and 1.19 (1.07-1.31) respectively.Conclusions: We found a weak association between the initiation of UTI treatment for ICS but not for LABA or LAMA.FootnotesCite this article as: European Respiratory Journal 2018 52: Suppl. 62, PA2270.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).",
author = "Henriksen, {Daniel Pilsgaard} and Laursen, {Christian B.} and Sterndorf, {Jane Winkel} and Davidsen, {Jesper R{\o}mhild} and Jesper Hallas",
year = "2018",
doi = "10.1183/13993003.congress-2018.PA2270",
language = "Udefineret/Ukendt",
volume = "52",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "Suppl. 62",

}

Long-acting inhalation treatment and the risk of urinary tract infection textendash a symmetry analysis. / Henriksen, Daniel Pilsgaard; Laursen, Christian B.; Sterndorf, Jane Winkel; Davidsen, Jesper Rømhild; Hallas, Jesper.

I: European Respiratory Journal, Bind 52, Nr. Suppl. 62, PA2270, 2018.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

TY - ABST

T1 - Long-acting inhalation treatment and the risk of urinary tract infection textendash a symmetry analysis

AU - Henriksen, Daniel Pilsgaard

AU - Laursen, Christian B.

AU - Sterndorf, Jane Winkel

AU - Davidsen, Jesper Rømhild

AU - Hallas, Jesper

PY - 2018

Y1 - 2018

N2 - Background: Long-acting muscarinic antagonists (LAMA) have previously been associated with increased risk of urinary tract infections (UTI), but the association is not well-established. Further, it has not been proven whether long-acting inhalation treatment (LAIT [long-acting bronchodilators] and inhaled corticosteroids [ICS]) show the same association. The study aimed to assess the association between LAIT and UTI treatment.Methods A prescription sequence symmetry analysis was employed on all Danish residents aged >=18 years from 2000-2016, who filled their first ever prescription for LAIT and a prescription of antibiotics targeting UTI within an interval of 30 days before or after the LAIT initiation. We calculated the sequence ratio (SR) and corresponding 95% confidence intervals. The SR is the ratio between subjects with LAIT prescribed before UTI treatment and subjects with LAIT prescribed after, which is a valid estimate of the incidence rate ratio. The attributable number of post-LAIT UTI treatment was also calculated.Results: A total of 36,048 persons were identified initiating their first LAIT and UTI treatment within a 30-day days. Of those, 26,017 (72 were females; 1,948 initiated LAIT before and 1,663 initiated LAIT after UTI treatment (SR 1.17, 1.10-1.25). The attributable number was 285 (14.6. Male- and female SR was 1.30 (95%CI 1.16-1.48) and 1.12 (1.04-1.21), respectively. Patients with a CCI>=3 had the strongest association (SR 1.35, 1.15-1.61). The SR initiating LAMA, LABA, and ICS was 1.02 (0.83-1.28), 1.24 (0.99-1.58), and 1.19 (1.07-1.31) respectively.Conclusions: We found a weak association between the initiation of UTI treatment for ICS but not for LABA or LAMA.FootnotesCite this article as: European Respiratory Journal 2018 52: Suppl. 62, PA2270.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

AB - Background: Long-acting muscarinic antagonists (LAMA) have previously been associated with increased risk of urinary tract infections (UTI), but the association is not well-established. Further, it has not been proven whether long-acting inhalation treatment (LAIT [long-acting bronchodilators] and inhaled corticosteroids [ICS]) show the same association. The study aimed to assess the association between LAIT and UTI treatment.Methods A prescription sequence symmetry analysis was employed on all Danish residents aged >=18 years from 2000-2016, who filled their first ever prescription for LAIT and a prescription of antibiotics targeting UTI within an interval of 30 days before or after the LAIT initiation. We calculated the sequence ratio (SR) and corresponding 95% confidence intervals. The SR is the ratio between subjects with LAIT prescribed before UTI treatment and subjects with LAIT prescribed after, which is a valid estimate of the incidence rate ratio. The attributable number of post-LAIT UTI treatment was also calculated.Results: A total of 36,048 persons were identified initiating their first LAIT and UTI treatment within a 30-day days. Of those, 26,017 (72 were females; 1,948 initiated LAIT before and 1,663 initiated LAIT after UTI treatment (SR 1.17, 1.10-1.25). The attributable number was 285 (14.6. Male- and female SR was 1.30 (95%CI 1.16-1.48) and 1.12 (1.04-1.21), respectively. Patients with a CCI>=3 had the strongest association (SR 1.35, 1.15-1.61). The SR initiating LAMA, LABA, and ICS was 1.02 (0.83-1.28), 1.24 (0.99-1.58), and 1.19 (1.07-1.31) respectively.Conclusions: We found a weak association between the initiation of UTI treatment for ICS but not for LABA or LAMA.FootnotesCite this article as: European Respiratory Journal 2018 52: Suppl. 62, PA2270.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

U2 - 10.1183/13993003.congress-2018.PA2270

DO - 10.1183/13993003.congress-2018.PA2270

M3 - Konferenceabstrakt i tidsskrift

VL - 52

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - Suppl. 62

M1 - PA2270

ER -